This invention relates to stable pharmaceutical compositions of the NMDA receptor agonist, (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propano l], methods of preparing such pharmaceutical compositions and methods of treating stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised using the pharmaceutical compositions.

Esta invenção relaciona-se às composições pharmaceutical estáveis do agonist do receptor de NMDA, (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propano l ], aos métodos de preparar tais composições pharmaceutical e aos métodos de tratar o curso, trauma do cabo spinal, ferimento traumatic do cérebro, dementia do multiinfarct, doenças degenerative do CNS tais como a doença de Alzheimer, dementia senile do tipo do Alzheimer, da doença de Huntington, da doença de Parkinson, do epilepsy, do sclerosis de lateral amyotrophic, da dor, do dementia do AIDS, de circunstâncias psychotic, de addictions de droga, de migraine, de hypoglycemia, de condições do anxiolytic, do incontinence urinary e de um evento isquêmico que levanta-se da cirurgia do CNS, da cirurgia aberta do coração ou do todo o procedimento durante que a função do sistema cardiovascular for comprometida usando as composições pharmaceutical.